ReviewInflammopharmacology2026
Drug-disease interactions in inflammation: mechanisms, clinical Impact, and future directions.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation is a complex biological response that varies significantly depending on the underlying disease or stress state, profoundly influencing the efficacy and safety of anti-inflammatory drugs. This review explores the multifaceted concept of drug-disease interactions in inflammatory conditions, highlighting how pathophysiological changes in autoimmune, metabolic, gastrointestinal, and infectious diseases modify pharmacokinetics and pharmacodynamics, thereby altering therapeutic responses and adverse effect profiles. We analyse a wide range of clinical studies and experimental models to elucidate the underlying mechanisms driving these interactions. The review further emphasizes personalized medicine approaches, including biomarker-guided therapies and pharmacogenomic insights, that enable tailored treatment strategies to improve patient outcomes. Strategies to optimize therapy in diverse disease states, such as drug repurposing and modulation in response to stress or comorbidities, are thoroughly examined. Additionally, emerging technologies and advanced experimental models are discussed to address current gaps and inform future research directions in conditional pharmacology. By synthesizing basic scientific knowledge with clinical practice, this comprehensive analysis aims to provide clinicians and researchers with critical insights necessary to enhance the safety and efficacy of anti-inflammatory treatments across a spectrum of inflammatory disorders.
Indexed as
Identifiers
41688589What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.